CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 1.57B
Enterprise value 1.27B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)496.63
Price/book (mrq)5.19
Enterprise value/revenue 403.70
Enterprise value/EBITDA -11.26

Trading information

Stock price history

Beta (5Y monthly) 2.10
52-week change 340.34%
S&P500 52-week change 33.90%
52-week high 348.40
52-week low 319.85
50-day moving average 333.18
200-day moving average 336.57

Share statistics

Avg vol (3-month) 3615.46k
Avg vol (10-day) 3335.13k
Shares outstanding 547.25M
Implied shares outstanding 6N/A
Float 844.02M
% held by insiders 10.31%
% held by institutions 1105.55%
Shares short (14 May 2023) 45.42M
Short ratio (14 May 2023) 49.21
Short % of float (14 May 2023) 413.93%
Short % of shares outstanding (14 May 2023) 411.46%
Shares short (prior month 13 Apr 2023) 45.18M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 310 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)-3,675.37%

Management effectiveness

Return on assets (ttm)-19.33%
Return on equity (ttm)-33.86%

Income statement

Revenue (ttm)3.15M
Revenue per share (ttm)0.07
Quarterly revenue growth (yoy)455.70%
Gross profit (ttm)-79.9M
EBITDA -112.96M
Net income avi to common (ttm)-118.64M
Diluted EPS (ttm)-2.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)278.39M
Total cash per share (mrq)5.89
Total debt (mrq)3.65M
Total debt/equity (mrq)1.21
Current ratio (mrq)19.03
Book value per share (mrq)6.41

Cash flow statement

Operating cash flow (ttm)-107.77M
Levered free cash flow (ttm)-54.6M